Medtech private investment is increasingly polarized, as record funding for scaled platforms comes at the expense of early-stage innovation, which is struggling to keep pace. Public markets have reemerged as the sector’s main exit engine, with a wave of IPOs offsetting muted M&A activity—though Boston Scientific’s acquisition streak remains a key outlier. And despite softer early-stage funding, overall deal value remains strong, led by large rounds for Aidoc, SetPoint Medical, and restor3d, as investors prioritize mature, AI-enabled platforms.
Read the full article: PitchBook Q3 2025 Medtech VC and PE Trends //
Source: https://pitchbook.com/news/reports/q3-2025-medtech-vc-and-pe-trends